Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May;21(5):338-344.
doi: 10.1016/j.clml.2020.12.025. Epub 2021 Jan 12.

Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome

Kiyomi Morita  1 , Elias Jabbour  1 , Farhad Ravandi  1 , Gautam Borthakur  1 , Joseph D Khoury  2 , Shimin Hu  2 , Guillermo Garcia-Manero  1 , William Wierda  1 , Ghayas Issa  1 , Naval Daver  1 , Naveen Pemmaraju  1 , Guillermo Montalban-Bravo  1 , Kelly A Soltysiak  1 , Sherry Pierce  1 , Carlos Bueso-Ramos  2 , Jorge Cortes  3 , Koji Sasaki  4
Affiliations

Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome

Kiyomi Morita et al. Clin Lymphoma Myeloma Leuk. 2021 May.

Abstract

Background: Acquisition of additional cytogenetic abnormalities (ACAs) in addition to Philadelphia chromosome is frequently observed in patients with chronic myeloid leukemia (CML) in advanced phase. The presence of core binding factor (CBF) translocations determines the diagnosis of acute myeloid leukemia regardless of blast percentage, and CBF rearrangements are rarely identified as ACAs.

Patients and methods: A retrospective chart review of patients with CML who had CBF rearrangement, t(8;21) or inv(16), in Philadelphia chromosome-positive clones was conducted. Additional cases of CML with CBF rearrangements were identified through literature review.

Results: Between August 1997 and December 2014, we identified 11 patients who had Philadelphia chromosome and CBF rearrangement in the same clones: 1 (9%) with t(8;21) and 10 (91%) with inv(16). Nine (82%) patients were in blast phase, and 2 (18%) in second chronic phase. Four (36%) patients received tyrosine kinase inhibitor monotherapy, 2 (18%) received tyrosine kinase inhibitor and chemotherapy, and 5 (45%) received chemotherapy only. Three (27%) patients achieved complete remission with incomplete count recovery, and 4 (36%) had no response after the initial therapy. Three (27%) patients underwent allogeneic stem cell transplantation. The median event-free survival and overall survival for the 11 patients were 2 months and 6 months, respectively. Literature review identified 14 patients with CML with CBF rearrangement with a median overall survival of 14 months.

Conclusion: Acquisition of CBF rearrangement in addition to Philadelphia chromosome is a rare phenomenon associated with poor prognosis. CBF rearrangements as ACAs in patients with CML can be considered high-risk features.

Keywords: Additional cytogenetic abnormalities; Blast phase; Chronic myeloid leukemia; Core binding factor; Tyrosine kinase inhibitor.

PubMed Disclaimer

Conflict of interest statement

Kiyomi Morita: This author declares no conflict of interest.

Elias Jabbour: This author declares research support and an advisory role with Adaptive, AbbVie, Amgen, Pfizer, Cyclacel LTD, Takeda, BMS.

Farhad Ravandi: This author declares research support and an advisory role with Macrogeni, Selvita, Cyclacel LTD, Menarini Ricerche, Xencor.

Gautam Borthakur: This author declares no conflict of interest.

Joseph D. Khoury: This author declares no conflict of interest.

Shimin Hu: This author declares no conflict of interest.

Guillermo Garcia-Manero: This author declares research support and an advisory role with Bristol Myers Squibb, Astex, and Helsinn, and research support from Amphivena, Novartis, AbbVie, H3 Biomedicine, Onconova, and Merck.

William Wierda: This author declares no conflict of interest.

Ghayas Issa: This author declares research support and an advisory role with Celegene, Syndax, and Novartis.

Naval Daver: This author declares no conflict of interest.

Naveen Pemmaraju: This author declares no conflict of interest.

Guillermo Montalban-Bravo: This author declares no conflict of interest.

Kelly A. Soltysiak: This author declares no conflict of interest.

Sherry Pierce: This author declares no conflict of interest.

Carlos Bueso-Ramos: This author declares no conflict of interest.

Jorge Cortes: This author declares research support, consultancy, and an advisory role with

Novartis, Pfizer, Takeda, Sun Pharma, BioPath Holdings, Telios, Astellas, Amphivena

Therapeutics, Arogs, BiolineRx, BMS, Daiichi Sankyo, Jazz, Immunogen, Merus, Tolero Pharmaceuticals, and Tovagene.

Koji Sasaki: This author declares an advisory role with Pfizer Japan.

Figures

Figure 1:
Figure 1:. Swimmer plot
A swimmer plot showing the clinical course of the 11 patients. The length of the bar represents the overall survival colored by the cytogenetic abnormalities. Ph, Philadelphia chromosome; CML, chronic myeloid leukemia; BP, blast phase; CP, chronic phase; TKI, tyrosine kinase inhibitor; MMR, major molecular response; CMR, complete molecular response.
Figure 2:
Figure 2:. Survival outcomes for patients with CML with CBF rearrangement.
(a) Event-free survival and overall survival for the 25 patients (11 patients from MD Anderson and 14 patients from literature review) with chronic myeloid leukemia (CML) who had Philadelphia chromosome and core binding factor (CBF) rearrangement in the same clones. EFS, event-free survival; OS, overall survival. (b) Overall survival for MD Anderson’s CML patients according to karyotypic abnormalities. OS, overall survival; CBF, core binding factor; CML, chronic myeloid leukemia; CBF-CML, CML with CBF rearrangement; CML-BP, CML in blast phase; ACAs, additional cytogenetic abnormalities; Ph, Philadelphia chromosome.
See this image and copyright information in PMC

References

    1. Hochhaus A, Larson RA, Guilhot F, et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. The New England journal of medicine. 2017;376:917–927. - PMC - PubMed
    1. Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016;34:2333–2340. - PMC - PubMed
    1. Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044–1054. - PMC - PubMed
    1. Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018;36:231–237. - PMC - PubMed
    1. Sasaki K, Strom SS, O’Brien S, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2:e186–193. - PMC - PubMed

Publication types

Substances